E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
patient with Clinically isolated syndrome |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10028245 |
E.1.2 | Term | Multiple sclerosis |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10063401 |
E.1.2 | Term | Primary progressive multiple sclerosis |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To observe the long term safety and tolerability of teriflunomide 14 mg once daily in a unique cohort of long term CIS patients |
|
E.2.2 | Secondary objectives of the trial |
To evaluate:
o the efficacy of teriflunomide in reducing conversion to CDMS or MS according to the 2010 McDonald criteria (annual MRI) for patients still CIS at long term
o the evolution of EDSS (annual assessment)
o Fatigue (annual FIS)
o Quality of life (annual SF36)
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Patients enrolled in TOPIC study and extension of TOPIC study and currently treated in French extension of TOPIC study who did not convert into MS.
- A baseline MRI scan (performed less than 2 months before baseline Visit ) confirming that patient is still in CIS status.
|
|
E.4 | Principal exclusion criteria |
- Contraindication for MRI, e.g., presence of pacemaker, metallic implants in high-risk areas (i.e., artificial heart valves, aneurysm/vessel clips), presence of metallic material (e.g., shrapnel) in high risk areas, known history of allergy to any contrast medium, or history of claustrophobia that would prevent completion of all protocol-scheduled MRIs. Hip implants are not contraindicated
- Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major systemic disease or procedure/medication making implementation of the protocol or interpretation of the study results difficult or that would put the patient at risk by participating in the study
- Patients with a congenital or acquired severe immunodeficiency, a history of cancer (except for basal or squamous cell skin lesions which have been surgically excised, with no evidence of metastasis), lymphoproliferative disease, or any patient who has received lymphoid irradiation
- Known history of active tuberculosis not adequately treated
- Persistent significant or severe infection
- History of drug or alcohol abuse
- Patient is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol
- Patients must not have used Adrenocorticotrophic hormone (ACTH) or systemic corticosteroids for 2 weeks prior to inclusion
- Prior use within 4 weeks before inclusion or concomitant use of cholestyramine
- Prior or concomitant use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate
- Prior or concomitant use of interferons, cytokine therapy, glatiramer acetate or intravenous immunoglobulins
- Prior or concomitant use of natalizumab (Tysabri®)
- Pregnant or breast-feeding women
- Women of childbearing potential not protected by effective contraceptive method of birth control and/or who are unwilling or unable to be tested for pregnancy.
- Women wishing to become pregnant during the course of the trial
- Patients with significantly impaired bone marrow function or significant anemia, leukopenia, or thrombocytopenia
•Hematocrit < 24% and/or
•Absolute white blood cell count < 4,000 cells/mm3 (µL) and/or
•Platelet count < 150,000 cells/mm3 (µL) and/or
•Absolute neutrophil ≤ 1,500 cells/mm3 (µL)
- Human immunodeficiency virus (HIV) positive patient
- Persisting elevations (confirmed by retest) of serum amylase or lipase greater than 2-fold the upper limit of normal
- Known history of chronic pancreatic disease or pancreatitis
- Liver function impairment or persisting elevations (confirmed by retest) of serum glutamic pyruvic transaminase (SGPT/ALT), serum glutamic oxaloacetic transaminase (SGOT/AST), or direct bilirubin greater than 1.5-fold the upper limit of normal
- Known history of active hepatitis
- Hypoproteinemia (e.g., in case of severe liver disease or nephrotic syndrome) with serum albumin < 3.0 g/dL
- Moderate to severe impairment of renal function, as shown by serum creatinine > 133 μmol/L (or > 1.5 mg/dL)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Long term evaluation of safety and tolerability of teriflunomide 14mg per day |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1. Conversion to definite MS based on MRI data as defined by the demonstration of dissemination of MRI lesions in time (based on the 2010 revised McDonald criteria, Appendix A) within 3 years.
2. Conversion to clinically definite MS based on clinical evaluation and annualized relapse rate (ARR), defined as number of relapses per patient-year.
3. Burden of disease (volume of abnormal brain tissue on MRI) at the last visit on treatment and other MRI variables at the last visit on treatment, including number and volume of Gd-enhanced T1 lesions, volume of T2 lesions, volume of T1 hypointense lesions and atrophy.
4. Time to disability progression (12 weeks), defined as a 1.0-point increase in EDSS score (or 0.5-point increase for baseline EDSS >5.5) confirmed after at least 12 weeks.
5. Proportion of disability-free subjects as assessed by the EDSS (annual evaluation).
6. Patient-reported fatigue based on the Fatique Impact Scale (annual evaluation).
7. Quality of life using SF-36 (annual evaluation) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. 3 years
2. annual evaluation
3. at the last visit on treatment
4. 12 weeks
5. annual evaluation
6. annual evaluation
7. annual evaluation |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |